Clinical trial
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
NCT00153088 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153088 |
|---|---|
| Title | INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy |
| Official title | A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathies |
| Intervention type | Drug |
| Interventions | Telmisartan capsule 40 mg, Placebo, Telmisartan capsule 80 mg |
| Enrollment | 527 |
| Start date | Jan 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 1, 2013 |
| Countries | Japan |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: